Key result
This editorial discusses the approval of the endothelin receptor antagonist ambrisentan for pulmonary arterial hypertension based on two pivotal trials.
This editorial discusses the evolution of medical therapies for pulmonary arterial hypertension, highlighting the FDA approval of ambrisentan based on two pivotal trials.
P ulmonary Arterial Hypertension (PAH) is a devastatingdisease that, until recently, had no effective medical therapy.In 1996, a prostacyclin, epoprostenol, was approved; since then, several therapies, including prostacyclin analogues and agents that modulate other vasoactive pathwaysendothelin receptor antagonists and phosphodiesterase inhibitors -have received approval.In this issue of Circulation, Galiè et al report the results of the 2 pivotal trials of the endothelin receptor antagonist, ambrisentan, that lead the US Food and Drug Administration to approve this agent in June 2007.
No takes yet. Share an insight, caveat, or question.
Harrison W. Farber (2008) conducted an editorial in Pulmonary Arterial Hypertension (PAH). Ambrisentan was evaluated. This editorial discusses the approval of the endothelin receptor antagonist ambrisentan for pulmonary arterial hypertension based on two pivotal trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: